What is Beta Bionics?
Beta Bionics is dedicated to the design, development, and commercialization of its innovative iLet® Bionic Pancreas System. This advanced device aims to autonomously manage insulin and/or glucagon doses using adaptive, self-learning control algorithms, integrated with continuous glucose monitoring and pump technology. The company operates as a for-profit, public benefit corporation and a Certified B Corporation, founded in 2015 with the core objective of enhancing health outcomes and quality of life for those managing diabetes and other glycemic dysregulation conditions. Beta Bionics operates across Massachusetts and California.
How much funding has Beta Bionics raised?
Beta Bionics has raised a total of $495.6M across 7 funding rounds:
Angel/Seed
$1M
Private Equity
$2.5M
Series B
$63M
Series C
$57M
Series D
$100M
Series E
$60M
Stock Offering
$212.1M
Angel/Seed (2016): $1M, investors not publicly disclosed
Private Equity (2017): $2.5M, investors not publicly disclosed
Series B (2019): $63M supported by ArrowMark Partners, Zealand Pharma A/S, Dexcom, LifeSci Venture Partners, and RTW Investments
Series C (2022): $57M featuring Perceptive Advisors, Novo Nordisk, Pura Vida Investments, LifeSci Venture Partners, RTW Investments, Eventide Asset Management, Farallon, Soleus Capital, and ArrowMark Partners
Series D (2023): $100M backed by OMEGA Funds Investment, Sands Capital, and Marshall Wace
Series E (2024): $60M with participation from Eventide Asset Management and Wellington Management
Stock Issuance/Offering (2025): $212.1M, investors not publicly disclosed
Key Investors in Beta Bionics
Perceptive Advisors
Perceptive Advisors is an investment firm established in 1999, managing approximately $7 billion in assets and specializing in funding innovative healthcare and life sciences technologies.
Novo Nordisk
Novo Nordisk is a global healthcare company dedicated to driving change to defeat serious chronic diseases, including diabetes, by advancing scientific innovation and improving access to medicines and delivery systems.
Pura Vida Investments
Pura Vida Investments is a hedge fund that concentrates its investments in both public and private companies within the healthcare industry, spanning all sectors and stages of development.
What's next for Beta Bionics?
The recent major strategic investment in Beta Bionics signals a pivotal phase for the company, likely enabling accelerated development and scaling of its iLet® Bionic Pancreas System. This influx of capital is expected to fuel further clinical trials, regulatory submissions, and the expansion of manufacturing capabilities. The company's focus on autonomous glycemic control positions it at the forefront of diabetes management technology, with this latest backing poised to drive market penetration and broader patient access to its life-changing solutions.
See full Beta Bionics company page
